Summarized by Masters of Longevity from BioSpace - Funding.
A funding announcement about a biotech’s preclinical program developing engineered proteins to target bacteria behind recurring bacterial vaginosis, and what the article covers about development and access.
Key Takeaways
- Precisio’s engineered lysins aim to kill BV bacteria while preserving beneficial microbes.
- The lysins are optimized for potency and activity against biofilms and resistant bacteria.
- New funding will move lead lysin candidates forward in preclinical development and testing.
